S A Grossman

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Management of pineal region tumors
    Jaishri O Blakeley
    Brain Cancer Program, Johns Hopkins University, Cancer Research Building 2, 1550 Orleans Street, Suite 1M16, Baltimore, MD 21231, USA
    Curr Treat Options Oncol 7:505-16. 2006
  2. pmc Phase I study of terameprocol in patients with recurrent high-grade glioma
    Stuart A Grossman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Neuro Oncol 14:511-7. 2012
  3. ncbi request reprint Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas
    S A Grossman
    Johns Hopkins Oncology Center, Baltimore 21231, MD, USA
    J Clin Oncol 19:3260-6. 2001
  4. pmc Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas
    Stuart A Grossman
    The New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD 21231, USA
    Neuro Oncol 7:32-40. 2005
  5. ncbi request reprint The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride
    Stuart A Grossman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 1000, and Massachusetts General Hospital, Boston, USA
    Clin Cancer Res 12:5174-81. 2006
  6. ncbi request reprint Cancer pain management in the 21st century
    Stuart A Grossman
    The Cancer Pain Service, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Oncology (Williston Park) 20:1333-9; discussion 1340-2, 1347-8, 1351. 2006
  7. ncbi request reprint Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol
    Stuart A Grossman
    1650 Orleans St, Room G93, The Sydney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 21:1485-91. 2003
  8. pmc Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma
    Stuart A Grossman
    NABTT CNS Consortium, 1550 Orleans Street, Baltimore, MD 21231, USA
    Neuro Oncol 10:190-8. 2008
  9. pmc Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas
    Stuart A Grossman
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231 1000, USA
    Neuro Oncol 10:608-16. 2008
  10. ncbi request reprint Current management of glioblastoma multiforme
    Stuart A Grossman
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Semin Oncol 31:635-44. 2004

Research Grants

  1. NABTT-Consortium Therapeutic Studies of CNS Malignancies
    Stuart Grossman; Fiscal Year: 2007
  2. RESEARCH TRAINING IN NEURO-ONCOLOGY
    Stuart Grossman; Fiscal Year: 2007

Detail Information

Publications67

  1. ncbi request reprint Management of pineal region tumors
    Jaishri O Blakeley
    Brain Cancer Program, Johns Hopkins University, Cancer Research Building 2, 1550 Orleans Street, Suite 1M16, Baltimore, MD 21231, USA
    Curr Treat Options Oncol 7:505-16. 2006
    ..Patients with tectal gliomas may undergo excision with or without postoperative radiation; however, they also may be observed with vigilant follow-up alone...
  2. pmc Phase I study of terameprocol in patients with recurrent high-grade glioma
    Stuart A Grossman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Neuro Oncol 14:511-7. 2012
    ..The long-term stability noted in some patients and the lack of associated myelosuppression suggest that terameprocol could be safely combined with radiation and temozolomide in newly diagnosed high-grade gliomas...
  3. ncbi request reprint Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas
    S A Grossman
    Johns Hopkins Oncology Center, Baltimore 21231, MD, USA
    J Clin Oncol 19:3260-6. 2001
    ..To determine the toxicity, efficacy, and pharmacology of suramin in patients with recurrent or progressive recurrent high-grade gliomas...
  4. pmc Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas
    Stuart A Grossman
    The New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD 21231, USA
    Neuro Oncol 7:32-40. 2005
    ..No clinical benefit was seen. The rapid deterioration seen in these patients could result from tumor growth or an effect of aprinocarsen on bloodbrain barrier integrity...
  5. ncbi request reprint The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride
    Stuart A Grossman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 1000, and Massachusetts General Hospital, Boston, USA
    Clin Cancer Res 12:5174-81. 2006
    ..This study was conducted to determine if the maximum tolerated dose and pharmacokinetics of PCB are affected by the concurrent use of enzyme-inducing antiseizure drugs (EIASD)...
  6. ncbi request reprint Cancer pain management in the 21st century
    Stuart A Grossman
    The Cancer Pain Service, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Oncology (Williston Park) 20:1333-9; discussion 1340-2, 1347-8, 1351. 2006
    ..An effective strategy to make alleviating pain a major health-care priority remains the primary challenge to effectively palliating patients with cancer pain...
  7. ncbi request reprint Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncol
    Stuart A Grossman
    1650 Orleans St, Room G93, The Sydney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 21:1485-91. 2003
    ..The control arm consisted of radiation with standard adjuvant BiCNU...
  8. pmc Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma
    Stuart A Grossman
    NABTT CNS Consortium, 1550 Orleans Street, Baltimore, MD 21231, USA
    Neuro Oncol 10:190-8. 2008
    ..Celecoxib administered during and after radiation is well tolerated. The potential difference in survival between the +EIASD and -EIASD groups deserves further evaluation...
  9. pmc Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas
    Stuart A Grossman
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231 1000, USA
    Neuro Oncol 10:608-16. 2008
    ..The total body clearance of karenitecin is significantly enhanced by the concurrent administration of EIASDs. This schedule of karenitecin, a novel lipophilic camptothecin analogue, has little activity in recurrent MG...
  10. ncbi request reprint Current management of glioblastoma multiforme
    Stuart A Grossman
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Semin Oncol 31:635-44. 2004
    ....
  11. pmc Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial
    Stuart A Grossman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 27:4155-61. 2009
    ..Talampanel is a well-tolerated, oral alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor blocker that could be beneficial in this disease...
  12. pmc Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide
    Stuart A Grossman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, Maryland 21231, USA
    Clin Cancer Res 17:5473-80. 2011
    ..As each of these is immunosuppressive, we conducted a prospective, multicenter study to follow CD4 counts over time and determine whether low CD4 counts were associated with adverse outcomes...
  13. pmc Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States
    Stuart A Grossman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA
    Clin Cancer Res 16:2443-9. 2010
    ..Results of these phase II studies are typically compared with the phase III European Organization for Research and Treatment of Cancer (EORTC) survival data that resulted in RT + TMZ becoming standard therapy...
  14. ncbi request reprint Leptomeningeal carcinomatosis
    S A Grossman
    The Johns Hopkins Oncology Center, 600 North Wolfe Street, Baltimore, MD, 21287, USA
    Cancer Treat Rev 25:103-19. 1999
    ..Further information on the mechanisms of neurotoxicity from antineoplastic agents is critical to providing better outcomes for this increasing common complication of cancer...
  15. ncbi request reprint Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma
    S A Grossman
    The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Clin Oncol 15:2596-603. 1997
    ..To evaluate the activity and toxicity of carmustine (BCNU) and cisplatin administered as a 72-hour continuous intravenous infusion before radiation in adults with newly diagnosed high-grade astrocytomas...
  16. ncbi request reprint Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme
    L Kleinberg
    Johns Hopkins Oncology Center, Baltimore, MD, USA
    J Clin Oncol 17:2593-603. 1999
    ..RSR13, a synthetic allosteric modifier of hemoglobin (HgB), is a novel radioenhancing agent that noncovalently binds to HgB, thereby reducing oxygen binding affinity and increasing tissue oxygen release to hypoxic tissues...
  17. ncbi request reprint Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy
    S A Grossman
    The Central Operations Office, The NABTT CNS Consortium, The Johns Hopkins Oncology Center, Baltimore, MD 21287, USA
    Cancer Chemother Pharmacol 42:118-26. 1998
    ..As existing chemotherapeutic agents are of limited benefit, clinical trials are underway to screen new drugs, such as 9-aminocamptothecin (9-AC), for activity in high grade astrocytomas...
  18. ncbi request reprint The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma
    L Kleinberg
    Division of Radiation Oncology, Johns Hopkins Oncology Center, Baltimore, MD, USA
    Int J Radiat Oncol Biol Phys 44:535-43. 1999
    ..To determine the effects of sequential versus concurrent administration of cranial radiotherapy and cisplatin/carmustine (BCNU) chemotherapy on survival and toxicity in newly diagnosed high-grade astrocytomas...
  19. doi request reprint Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation
    Elizabeth R Gerstner
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Neurology 70:401-2. 2008
  20. pmc Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study
    Surasak Phuphanich
    The New Approaches to Brain Tumor Therapy CNS Consortium, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Neuro Oncol 7:177-82. 2005
    ..The pharmacology of PB appears to be affected by concomitant administration of P450-inducing anticonvulsants...
  21. ncbi request reprint Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study
    L Kleinberg
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 2410, USA
    J Clin Oncol 20:3149-55. 2002
    ..RSR13, a synthetic allosteric modifier of hemoglobin, is a radiation-enhancing agent that noncovalently binds to hemoglobin, reduces oxygen-binding affinity, and increases oxygen unloading to hypoxic tissue...
  22. doi request reprint Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme
    Matthew J McGirt
    Departments of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    J Neurosurg 110:583-8. 2009
    ..The authors reviewed their initial experience utilizing combined Gliadel, TMZ, and radiation therapy for the treatment of GBM...
  23. pmc Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial
    Jon Weingart
    New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD, USA
    J Clin Oncol 25:399-404. 2007
    ....
  24. pmc Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11
    Tracy T Batchelor
    Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 6:21-7. 2004
    ..Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations...
  25. ncbi request reprint Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
    L Burt Nabors
    New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD 21231, USA
    J Clin Oncol 25:1651-7. 2007
    ..This multi-institutional phase I trial was designed to determine the maximum-tolerated dose (MTD) of cilengitide (EMD 121974) and to evaluate the use of perfusion magnetic resonance imaging (MRI) in patients with recurrent malignant glioma...
  26. ncbi request reprint Treatment of relapsed central nervous system lymphoma with high-dose methotrexate
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:5643-6. 2004
    ..The optimal management of these patients has not been determined. We performed a multicenter, retrospective study of high-dose methotrexate in patients with relapsed central nervous system lymphoma...
  27. pmc A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas
    Jana Portnow
    The Johns Hopkins Oncology Center, Baltimore, MD 21231 1000, USA
    Neuro Oncol 4:22-5. 2002
    ..2). These results suggest that a selective COX-2 inhibitor appears to be as effective as dexamethasone in prolonging survival in a rat brain tumor model...
  28. ncbi request reprint Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management
    Lawrence R Kleinberg
    Johns Hopkins Oncology Center, Johns Hopkins University, 401 North Broadway, Baltimore, MD 21231, USA
    Cancer Invest 22:1-9. 2004
    ..Therefore, the possibility of necrosis/treatment effect should be considered for each patient with radiographic findings suspicious for local recurrence...
  29. ncbi request reprint Herpes simplex encephalitis in a patient with recurrent pituitary adenoma receiving radiation therapy
    Tien Peng
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA
    Am J Clin Oncol 30:664-5. 2007
  30. ncbi request reprint Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07
    Tracy Batchelor
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 21:1044-9. 2003
    ..A multicenter, phase II study of single-agent, intravenous methotrexate in newly diagnosed non-AIDS-related primary CNS lymphoma was conducted in the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium...
  31. ncbi request reprint Primary central nervous system lymphomas
    Julette F Batara
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Curr Opin Neurol 16:671-5. 2003
    ..The outcome for patients with PCNSL is rapidly improving with new treatment strategies. This review focuses on recent advances, investigations, and controversies in the management of these increasingly important malignancies...
  32. ncbi request reprint Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial
    Alessandro Olivi
    The New Approaches to Brain Tumor Therapy CNS Consortium, 1650 Orleans St, Room G93, The Sydney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 21:1845-9. 2003
    ....
  33. ncbi request reprint Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials
    Kathryn A Carson
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 25:2601-6. 2007
    ..Prognostic factor analyses have proven useful in predicting outcome in patients with newly diagnosed malignant glioma. Similar analyses in patients with recurrent glioma could affect the design and conduct of clinical trials substantially...
  34. pmc The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas
    David E Gerber
    Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Neuro Oncol 9:47-52. 2007
    ....
  35. doi request reprint Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study
    Jaishri O Blakeley
    Johns Hopkins University School of Medicine, Cancer Research Building II, 1550 Orleans Street, Suite 1M16, Baltimore, MD, 21231, USA
    J Neurooncol 91:51-8. 2009
    ..This study investigated the use of microdialysis to assess intratumoral drug distribution in patients with recurrent high grade gliomas (HGG)...
  36. ncbi request reprint Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomas
    Stuart A Grossman
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Semin Oncol 30:19-22. 2003
    ..Improving outcome in high-grade gliomas requires an emphasis on discovering novel therapies and improving the design of adjuvant trials...
  37. pmc Controversies in the adjuvant therapy of high-grade gliomas
    Matthias Holdhoff
    Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Oncologist 16:351-8. 2011
    ..be extrapolated to patients aged >70 and to patients with lower grade gliomas? and (d) How should novel therapeutic approaches be added to radiation and temozolomide in clinical trials for patients with newly diagnosed glioblastoma?..
  38. pmc Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literature
    Mary Y Armanios
    Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Neuro Oncol 6:259-63. 2004
    ..The patient died 2 weeks after the diagnosis was established. The patient receiving the donor liver also developed GBM. We present a case study, review of the literature, and suggested interventions to minimize the risk of transmission...
  39. ncbi request reprint An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial
    Stephen B Tatter
    Department of Neurosurgery, Wake Forest University, Winston Salem, North Carolina, USA
    J Neurosurg 99:297-303. 2003
    ..In this study the authors evaluated the safety and performance of the GliaSite Radiation Therapy System (RTS) in patients with recurrent malignant brain tumors who were undergoing tumor resection...
  40. doi request reprint Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme
    Matthias Holdhoff
    Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Cancer Research Building II, Suite 1 M 16 1550 Orleans Street, Baltimore, MD, 21231, USA
    J Neurooncol 97:241-5. 2010
    ....
  41. pmc Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study
    John J Laterra
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Neuro Oncol 6:15-20. 2004
    ..However, overall survival is not significantly improved when compared with the New Approaches to Brain Tumor Therapy GBM database or other comparable patient populations...
  42. pmc Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide
    Ana De Jesus
    Johns Hopkins Hospital, Baltimore, USA
    J Neurooncol 94:445-8. 2009
    ..This case highlights the potential for severe opportunistic infections in this patient population after severe immunosuppression...
  43. pmc Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma
    Rachel L Derr
    c o The NABTT CNS Consortium, Cancer Research Building 2, Suite 1M 16, 1550 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 27:1082-6. 2009
    ..Time-weighted mean glucose and mean glucocorticoid dose were calculated for each patient using all values collected regularly in follow-up. The primary outcome was survival...
  44. ncbi request reprint Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors
    Anuj K Mahindra
    The Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231 1000, USA
    J Neurooncol 63:263-70. 2003
    ..This prompted the present review of the clinical features and risk factors for PCP in the human immunodeficiency virus (HIV) negative brain tumor population...
  45. ncbi request reprint Central nervous system cancers in first-degree relatives and spouses
    S A Grossman
    Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Cancer Invest 17:299-308. 1999
    ..Although this hypothesis requires further study, it is plausible given the known associations in animals and humans between high-grade astrocytomas and radiation, toxic chemicals, and viruses...
  46. ncbi request reprint Feasibility of quantitative pain assessment in outpatient oncology practice
    D J Rhodes
    Johns Hopkins Hospital and St Agnes Hospital, Baltimore, MD, USA
    J Clin Oncol 19:501-8. 2001
    ..Pain score collection identified a high prevalence of pain, patient subgroups at risk for pain, and a significant proportion of patients with pain that was neither evaluated nor treated by their oncologists...
  47. pmc Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium
    Ramsis K Benjamin
    Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 6:65-74. 2004
    ..In doing so we provide a rationale for the use of this technology by a National Cancer Institute consortium, New Approaches to Brain Tumor Therapy, to measure levels of drugs in brain tissue as part of phase 1 trials...
  48. ncbi request reprint Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxis
    David E Gerber
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer 109:300-5. 2007
    ..Therefore, we conducted a retrospective review of postoperative meningioma patients receiving contemporary VTE prophylaxis and diagnostic methods to define the current incidence of and risk factors for symptomatic VTE in this population...
  49. ncbi request reprint A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting
    E Antonio Chiocca
    The NABTT CNS Consortium, Baltimore, MD 21231, USA
    Mol Ther 10:958-66. 2004
    ..In 2 patients who underwent a second resection 3 months after ONYX-015 injection, a lymphocytic and plasmacytoid cell infiltrate was observed. Injection of ONYX-015 into glioma cavities is well tolerated at doses up to 10(10) pfu...
  50. ncbi request reprint Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature
    Johann C Brandes
    Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Cancer Invest 24:283-7. 2006
    ..Thymidine and carboxypeptidase were not available. Dialysis was unsuccessful in removing pemetrexed. Theoretical and practical approaches to management of similar cases are presented...
  51. ncbi request reprint Epigenetic silencing of multiple genes in primary CNS lymphoma
    Linda C Chu
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Int J Cancer 119:2487-91. 2006
    ..Our study provides insight into the epigenetic alterations in PCNSL and provides potential biomarkers of disease...
  52. doi request reprint Transmission of glioblastoma multiforme after bilateral lung transplantation
    Hongbin Chen
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA
    J Clin Oncol 26:3284-5. 2008
  53. ncbi request reprint Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma
    David E Gerber
    The New Approaches to Brain Tumor Therapy NABTT CNS Consortium, 1550 Orleans Street, Cancer Research Building II, Suite 1M16, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 59:817-23. 2007
    ..Because these collections are cumbersome and at times unreliable, the use of a calculated CrCl was evaluated as a potential alternative...
  54. ncbi request reprint Tissue and tumor distribution of C-penclomedine in rats
    S O'Reilly
    The Johns Hopkins Oncology Center, Baltimore, Maryland 21287, USA
    Clin Cancer Res 2:541-8. 1996
    ..The finding of penclomedine in normal brain tissue indicates not only that this drug may be useful in tumors with normal blood-brain barrier function, but also that it may be directly neurotoxic...
  55. ncbi request reprint ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas
    Michael B Streiff
    Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer 100:1717-23. 2004
    ..To investigate the pathogenesis of VTE and facilitate targeted prophylaxis strategies, the authors aimed to characterize VTE risk factors in these patients...
  56. ncbi request reprint Does decompressive surgery improve outcome in patients with metastatic epidural spinal-cord compression?
    David E Gerber
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Nat Clin Pract Neurol 2:10-1. 2006
  57. ncbi request reprint Management of venous thromboembolism in patients with primary and metastatic brain tumors
    David E Gerber
    Departments of Oncology, Medicine, and Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Clin Oncol 24:1310-8. 2006
    ..When intracranial hemorrhage does occur, it is often due to overanticoagulation, requiring prompt anticoagulation reversal and neurosurgical consultation...
  58. ncbi request reprint Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme
    Tom Mikkelsen
    Department of Neurology, Henry Ford Health System, Detroit, Michigan 48202, USA
    Invest New Drugs 25:259-63. 2007
    ..This study examined the efficacy, safety and pharmacokinetics of oral CAI in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM) in an open-label, single arm non-randomized phase 2 trial...
  59. pmc Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma
    Steven Brem
    Department of Interdisciplinary Oncology and Neurosurgery, University of South Florida College of Medicine and Neuro Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL 33620, USA
    Neuro Oncol 7:246-53. 2005
    ..Although serum copper was effectively reduced by diet and penicillamine, this antiangiogenesis strategy did not improve survival in patients with glioblastoma multiforme...
  60. ncbi request reprint Central nervous system cancers: Clinical Practice Guidelines in Oncology
    Steven S Brem
    J Natl Compr Canc Netw 3:644-90. 2005
  61. ncbi request reprint Adult cancer pain
    Robert Swarm
    National Comprehensive Cancer Network
    J Natl Compr Canc Netw 5:726-51. 2007
  62. pmc Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma
    Surasak Phuphanich
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Neuro Oncol 10:617-23. 2008
    ..Further study of atrasentan with radiation therapy and temozolomide in newly diagnosed GBM is warranted to evaluate the efficacy of this novel agent...
  63. ncbi request reprint Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma
    Beela S Mathew
    Regional Cancer Center, Trivandrum, India
    Cancer Treat Rev 29:105-19. 2003
    ..It also provides recommendations for Pneumocystis prophylaxis for this patient population...
  64. ncbi request reprint Methylated tumor-specific DNA as a plasma biomarker in patients with glioma
    Kyle D Weaver
    Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Cancer Invest 24:35-40. 2006
    ..Patients with systemic malignancies have substantial quantities of tumor-specific DNA in their plasma which may serve as a potential biomarker for tumor burden. This approach has not been studied in gliomas...
  65. ncbi request reprint Initial response to glucocorticoids
    Beela S Mathew
    Department of Radiation Oncology, Regional Cancer Center, Trivandrum, India
    Cancer 106:383-7. 2006
    ..This retrospective chart review was designed to estimate the prognostic significance of a clinical or radiologic response to initial glucocorticoid therapy...
  66. pmc Penetration of intra-arterially administered vincristine in experimental brain tumor
    Frances M Boyle
    Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital, Sydney, NSW 2065, Australia
    Neuro Oncol 6:300-5. 2004
    ..The lack of penetration of vincristine into brain tumor and the paucity of single-agent activity studies suggest that vincristine should not be used in the treatment of primary brain tumors...
  67. ncbi request reprint Central nervous system cancers
    Steven S Brem
    H Lee Moffitt Cancer Center and Research Institute
    J Natl Compr Canc Netw 6:456-504. 2008

Research Grants4

  1. NABTT-Consortium Therapeutic Studies of CNS Malignancies
    Stuart Grossman; Fiscal Year: 2007
    ..abstract_text> ..
  2. RESEARCH TRAINING IN NEURO-ONCOLOGY
    Stuart Grossman; Fiscal Year: 2007
    ..This program is designed to provide well-rounded research training to trainees and to develop them as the next generation of investigators in neuro-oncology. ..